NEW YORK (Legal Newsline) - Public pension funds that accused AstraZeneca of misleading investors about the efficacy of the company’s Covid 19 in order to facilitate a stock-funded acquisition failed to identify any false statements or a motive for committing fraud, the Second Circuit Court of Appeals ruled, upholding the dismissal of the case.